Profile of mirabegron in the treatment of overactive bladder: place in therapy

Abstract: Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature.

Keywords: mirabegron, overactive bladder disorder, antimuscarinics

Introduction
Mirabegron is the first of a new class of drugs licensed for the management of overactive bladder syndrome (OAB) in over 30 years. It is a human β3-adrenoceptor agonist developed by Astellas Pharma Inc. for the treatment of OAB.

OAB is defined as urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence, in the absence of any other pathology.1

OAB occurs in both men and women and it has a significant impact on the quality of life. Treatment focuses on lifestyle modification initially, such as weight loss, fluid management, avoiding or reducing caffeine, alcohol, and other bladder irritants, and bladder training. If this fails, antimuscarinics are the first-line treatment option.

Mirabegron has been gaining popularity in the last few years for treating patients with OAB as an alternative to antimuscarinics.

It was licensed for the treatment of OAB and has been approved for use in Japan in 2011 (Betanis), USA and Canada in 2012 (Myrbetriq), and Europe in 2013 (Betmiga).

This article will look at mirabegron in the literature and review its pharmacokinetics, adverse effects, and effectiveness in treating OAB.

Pharmacokinetics and mechanism of action
Detrusor relaxation is mainly mediated by the cyclic adenosine monophosphate pathway. Mirabegron is a potent and selective β3-adrenoceptor agonist. It causes increased cyclic adenosine monophosphate concentrations in the rat bladder tissue and shows a bladder relaxant effect.2,3 It also results in relaxation of bladder smooth muscle in rat and human isolated tissue.

The chemical name of mirabegron is 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-[(2R)-2-hydroxy-2-phenylethyl]amino)ethyl]phenylacetamide and the chemical formula is C21H24N4O2S (Figure 1).
Mirabegron is rapidly absorbed after oral administration, with the time to maximum plasma concentration (T<sub>max</sub>) being approximately 3 hours and the terminal plasma half-life being 50 hours.

About 70% of the compound is bound to plasma proteins, mainly to albumin and then to α1-acid glycoprotein.<sup>3-5</sup>

It has an oral bioavailability between 24% and 53%, which differs with dose and gender. The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean maximum plasma concentration (C<sub>max</sub>) and area under the plasma concentration–time curve (AUC) increased more than dose proportionally over the dose range.<sup>3,4</sup>

The C<sub>max</sub> and AUC of mirabegron are not affected by the age of the patient. The C<sub>max</sub> and AUC are approximately 40%–50% higher in females than in males. Gender differences in C<sub>max</sub> and AUC are mainly the result of differences in body weight and bioavailability.

Mirabegron is metabolized in the liver mainly by cytochrome P450 (CYP) 3A4, and CYP2D6 plays a minor role in its metabolism. Appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6.<sup>3,6,7</sup>

It has a biological half-life of 50 hours, is cleared by multiple mechanisms with no single predominating clearance pathway, and is excreted in both urine (55%) and feces (34%).<sup>3</sup>

**Mirabegron trials**

The clinical efficacy and safety of mirabegron have been assessed in multiple Phase II and Phase III clinical trials.

This includes the Phase Ia and Iib trials by Chapple et al. In 2013, they reported the results of the BLOSSOM trial.<sup>8</sup> This was a proof-of-concept, randomized, double-blind, parallel-group, Phase Ia dose-ranging trial with mirabegron in patients with OAB. Tolterodine and placebo were used as controls. Two hundred and sixty patients were enrolled from 31 European sites. The trial showed a statistically significant reduction in the mean micturition frequency from baseline by 17% with 100 mg and 18% with 150 mg of mirabegron, when compared with placebo, which resulted in a 9% reduction, and tolterodine, which resulted in an 11% reduction. Mirabegron was also significantly superior in reducing the mean volume voided per micturition, mean number of incontinence episodes, nocturia episodes, urgency incontinence episodes, and urgency episodes per 24 hours.<sup>3</sup>

This was followed up in the Dragon trial, which enrolled 919 patients.<sup>9</sup> The patients were randomized to five groups: placebo, and once-daily mirabegron 25, 50, 100, and 200 mg for 12 weeks. This showed statistically significant dose-dependent reduction in the mean micturition frequency with 50, 100, and 200 mg of mirabegron, compared with placebo. This trial also showed that mirabegron significantly increased the mean volume voided per micturition, decreased the mean number of incontinence episodes, urgency incontinence episodes, and urgency episodes per 24 hours.

Nitti et al also looked at the urodynamic parameters in men with lower urinary tract symptoms and bladder outflow obstruction treated with mirabegron.<sup>10</sup> Two hundred male patients were enrolled. Seventy patients received mirabegron 50 mg, 65 received mirabegron 100 mg, and 65 received placebo. Urodynamic parameters assessed were the change from baseline to the end of treatment in maximum urinary flow rate (Q<sub>max</sub>) and detrusor pressure at Q<sub>max</sub> (PdetQ<sub>max</sub>). The study showed that mirabegron did not adversely affect the voiding urodynamic parameters such as the bladder contractility index and the bladder voiding efficiency after 12 weeks of treatment, compared with placebo.

Clinical trial evidence for mirabegron is based on four primary Phase III randomized controlled trials (RCTs):

- **Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO), Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES), A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN), and Yamaguchi et al.**

ARIES, CAPRICORN, SCORPIO, and the Yamaguchi et al RCTs were all multiple-arm trials in patients with symptoms of OAB. SCORPIO and ARIES evaluated the clinical effectiveness of mirabegron (50 and 100 mg) compared to placebo. CAPRICORN evaluated mirabegron (50 and 25 mg) against placebo. Yamaguchi et al evaluated the efficacy and safety of mirabegron 50 mg in a Japanese population with OAB against tolterodine and placebo over 16 weeks.

SCORPIO trial was a multicenter trial conducted by Khullar et al that included Europe and Australia.<sup>11</sup> It was a randomized, double-blind, parallel-group, placebo- and
active-controlled Phase III trial in which 1,978 patients were enrolled. All patients had placebo for 2 weeks and then they were randomized. Of them, 493 patients received mirabegron 50 mg, 496 received mirabegron 100 mg, 495 received tolterodine, and 494 received a placebo for a total of 12 weeks.

The trial showed a statistically significant decrease in the mean number of micturitions from baseline with 50 (−1.93) and 100 mg (−1.77) of mirabegron and in the mean number of incontinence episodes (−1.57 with 50 mg and −1.46 with 100 mg) per 24 hours, compared to placebo. A post hoc analysis of the SCORPIO trial showed that both mirabegron doses were effective in improving the coprimary efficacy endpoints versus placebo in antimuscarinic treatment-naïve patients and in patients whose condition failed to respond to previous antimuscarinic therapy, regardless of the reason for discontinuation.

The ARIES trial was a North American, multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase III trial carried out by Nitti et al. In this, 1,328 patients were enrolled and randomized to receive either placebo, mirabegron 50 mg, or mirabegron 100 mg for 12 weeks. The trial showed a statistically significant reduction in the number of incontinence episodes from baseline with both doses of mirabegron (50 mg [−1.47] and 100 mg [−1.63]), compared to placebo (−1.13) (P<0.05). There was also a significant reduction in the number of micturitions per 24 hours in both mirabegron 50 mg (−1.66) and 100 mg (−1.75) groups, compared to placebo (−1.05) (P<0.05).

The CAPRICORN trial was a Phase III, randomized, double-blind, placebo-controlled trial carried out by Herschorn et al in Europe and North America. The objective was to assess the efficacy and tolerability of mirabegron 25 and 50 mg once daily versus placebo in patients with OAB. In this trial, 1,306 patients were enrolled and randomized. Of these, 433 received mirabegron 25 mg, 440 received mirabegron 50 mg, and 433 received placebo for 12 weeks. The primary endpoints were changes in the mean number of incontinence episodes and micturitions per 24 hours at the final visit. Both mirabegron 25 and 50 mg groups showed a reduction in incontinence episodes in 24 hours (−1.36 and −1.38, respectively), when compared to placebo (−0.96) (P<0.05). There was also a reduction in the number of micturition episodes in 24 hours (−1.65 for mirabegron 25 mg and −1.60 for mirabegron 50 mg), in comparison to placebo (−1.18) (P<0.05). The results showed that both mirabegron groups demonstrated statistically significant improvements when compared to placebo. However, mirabegron 50 mg showed greater improvement in the mean volume voided per micturition and the mean number of incontinence episodes per 24 hours.

Yamaguchi et al conducted a Phase III RCT evaluating the efficacy and safety of mirabegron 50 mg in a Japanese population with OAB. A total of 1,139 patients were enrolled and randomized to receive placebo, mirabegron 50 mg, or tolterodine 4 mg for 16 weeks. The primary efficacy endpoint was the change in the mean number of micturitions per 24 hours from baseline to final visit.

In this trial, mirabegron 50 mg once daily showed a statistically significant improvement (P<0.05) in the mean number of micturitions per 24 hours (−1.67 vs −0.86) urgency episodes per 24 hours (−1.85 vs −1.37), incontinence episodes per 24 hours (−1.12 vs −0.66), urgency incontinence episodes per 24 hours (−1.01 vs −0.6), and volume voided in each micturition (24.3 vs 9.71), when compared to placebo.

Abrams et al conducted the SYMPHONY trial. This was a Phase II, factorial design, randomized, double-blind, parallel-group, placebo- and monotherapy-controlled trial conducted at 141 sites in 20 European countries. It included both male and female patients aged 18 years or above with symptoms of OAB for at least 3 months. In this trial, 1,306 patients were randomized to 12 weeks of treatment in one of 12 groups: six combination groups (solifenacin 2.5, 5, or 10 mg plus mirabegron 25 or 50 mg), five monotherapy groups (solifenacin 2.5, 5, or 10 mg, or mirabegron 25 or 50 mg), or placebo.

The trial showed that combination therapy with solifenacin and mirabegron significantly improved the mean voided volume, micturition frequency, and urgency, compared with solifenacin 5 mg monotherapy. All combinations were well tolerated, with no important additional safety findings compared with monotherapy or placebo.

Recently, results from the BESIDE study were published. Macdiarmid et al conducted a randomized, double-blind, parallel-group, multicenter, Phase IIIb study. A total of 2,174 patients were randomized to a combination of mirabegron 50 mg and solifenacin 5 mg (n=727), or solifenacin 5 mg (n=728), or solifenacin 10 mg (n=719). The study showed that more patients on the combination achieved clinically meaningful improvements in incontinence and micturition frequency. The improvements were accompanied by similar improvements in Patient Perception of Bladder Condition, symptom bother, and health-related quality of life.
Side effect profile

Mirabegron does not have the same adverse effects as anticholinergic agents and, thus, may be more tolerable in some individuals who experience side effects with anticholinergics. Mirabegron 50 mg caused dry mouth with an incidence similar to placebo and significantly lower than antimuscarinics. However, patients who use mirabegron could suffer from side effects such as raised blood pressure, tachycardia, urinary tract infections, constipation, headache, back pain, and dizziness.17

Less common side effects include palpitations, atrial fibrillation, utricarial, and joint pain and swelling.12,14,17

In 2015, the Medicines and Healthcare Products Regulatory Agency issued a warning stating that mirabegron is contraindicated in patients with severe uncontrolled hypertension, and advice about regular monitoring is being introduced because of cases of severe hypertension. It stated that mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg, or both). It also recommended that blood pressure should be checked before starting treatment and monitored regularly during treatment, especially in patients with hypertension.

Conclusion

There are quite a number of RCTs looking at mirabegron, where >27,000 patients have been included.18 The majority of these trials show that mirabegron 50 mg was efficacious in reducing the frequency of micturition and urgency urinary incontinence episodes, as well as more tolerable in individuals who cannot tolerate antimuscarinics.

Currently, a number of ongoing trials further assess the safety and efficacy of mirabegron in combination with other drugs, such as the PLUS trial which looks at the safety and efficacy of mirabegron when taken with tamsulosin.

Disclosure

Hashim Hashim is or has been an investigator, lecturer, and consultant for pharmaceutical companies producing or developing drugs for overactive bladder syndrome. The authors report no conflicts of interest in this work.

References
